The Online Resource for Massachusetts Poverty Law Advocates

Ethnic psychopharmacology

Date: 
11/30/2002
Author: 
Center for Public Representation

A review of the way that psychiatric medications may effect people depending on their ethnic backgrounds.

Q&A on Ethnic Psychopharmacology
Prepared by Center for Public Representation
October 2002

    Q. When asked by clients of color about their legal rights regarding psychiatric medication, are there any special issues or concerns of which I should make them aware?
    A. Yes. There is a growing body of research that suggests that people respond differentlyto psychotropic medication based on their ethnic background. This area of study is called EthnicPsychopharmacology. African Americans, Asians, Hispanics, and Caucasians have differentresponses to the same dosages of commonly prescribed psychotropic medication. Furthermore,recent immigrants from Asia, Africa, and from Latin American countries have different responsesto such than do persons of the same racial background who have lived in this country for manyyears (Mendoza et al 1991, Mendoza and Smith 2000). Researchers have found that bothbiological and environmental differences among ethnicities play major roles in an individual'sresponse to psychotropic medications. Despite the amount of research, its clear conclusions, andits important implications, many clinicians, advocates and clients remain uninformed.  

(See footnote 1) 

 

P&Aadvocates should be prepared to alert their minority clients to these issues and to advocate for theplanning, design, and implementation of culturally responsive and ethnic specific treatmentmodalities in every element of the service system.
    Research dating back as far as the 1920s documents findings of differences in responses to medications based on ethnicity. The initial research was done with cocaine, ephedrine, atropineand scopolamine (Hu et al 1991). Since then, a large body of biological data has supported theearly findings. Although the bulk of this research has traced differences in the effects ofmedications between and among African American, Asians, and Caucasians, research regardingother ethnic groups, primarily Native Americans and Hispanics, is growing (Mendoza et al 1991).
    Multiple studies have concluded that African Americans are more likely than other ethnicgroups to be misdiagnosed and over medicated (Lawson 2000, Adebimpe, Caminah-Bacote 2002,Baker et al 1999, Lin et al 1995). Because African Americans are repeatedly misdiagnosed withschizophrenia, depressive disorders are often not diagnosed (Lawson 2000). Consequently,African Americans receive more antipsychotic medication, are more likely than Caucasians todevelop tardive dyskinesia, and may have an increased likelihood of incidents of neuroleptictoxicity (Lawson 2000). Likewise, African Americans have more side effects than Caucasianswith treated with the standard dosage of lithium (Caminah-Bacote 2002, Lin, Poland 1996,Lawson 2000). However, research has not yet conclusively established the advisability of usinglower doses of psychotropics across the board with African American clients.
    As used in the relevant research, the term “Hispanic” refers to Mexicans, CentralAmericans, Cubans, Puerto Ricans, South Americans, and individuals of Spanish descent living inthe United States. While some research has found similarities in responses to psychiatric treatmentfor Hispanics as a whole, there are also differences within the subgroups. Hispanics tend torespond better to lower doses of Risperidone, for example, and they have a higher rate of adverseside effects (Lawson 2000).  

(See footnote 2) 

 

Doctors in Latin America typically prescribe lower doses of psychiatric medications than their counterparts in the United States. Interestingly, the rate ofimprovement is faster in Latin American countries (Campinah-Bacote 2002, Adams 1984,Mendoza 1991). For example, in Argentina and Chile, patients are typically treated withClozapine at 300 mg/day which is less than the amount typically used in the United States tosuccessfully treat Caucasians (Mendoza and Smith 2000).
    The term “Asian” refers to Chinese, Filipino, Indian, Korean, Vietnamese, Japanese and
other groups of people from the continent of Asia. Many of the ethnic psychopharmacologystudies have concluded that Asian patients require lower doses of antipsychotic medications thanCaucasian patients (Campinah-Bacote 2002, Lin et al 1999, Lin et al 1995 Pi 2000). Research inthis area has had an impact on recommended dosage levels for Asians. Researchers havesuggested that dosage level start at half of the standard dosage for all psychiatric medication(Campinah-Bacote 2002, Lin et al 1999, Lin et al 1995, Pi 2000). There is also some data tosuggest that Asians may be at an increased risk of developing acute dystonic reactions fromantipsychotics ( Pi 2000).
    There are yet very few conclusions about the long term effects of medication based onethnicity. For example, the relationship is between ethnicity and neuroleptic malignant syndromeis unknown (Pi 2000). As noted earlier, African Americans have a higher rate of tardivedyskinesia (Lawson 2000). Although the reasons are unknown, it may be due to a biologicalfactor or because higher numbers of African Americans are given antipsychotic medications.
     Overall, this research provides significant information that P&A clients need to knowwhen making decisions about psychiatric medication. In most circumstances, individuals have aright to determine the nature and extent of their medical care. The legal doctrine of informed consent requires doctors to explain the treatment options to their patients and to obtain consentprior to administering treatment. The doctrine is usually described as having three parts: (1) the doctor's duty to disclose in a reasonable manner all significant medical information that thephysician possesses or reasonably should possess that is material to an intelligent decision by thepatient (information): (2) the ability of the individual to understand the information provided(competence or capacity); and, (3) that the consent is given free of coercion (voluntariness).  

(See footnote 3) 

 

Using this standard, an argument can be made that a reasonable person would consider, ofrexample, knowledge of an increased risk of adverse side effects significant in making his or herdecision to consent to treatment. Therefore, it can be argued that the doctor has a duty to discloseinformation about the potential differing impact of psychiatric medications to a person of color.
    As advocates, is it also important for us to let our clients know about the existence of thisinformation and to urge them to discuss it with their doctors. The Center for PublicRepresentation has developed a training module which it has presented, often with the assistanceof a clinician, to professional, family and client groups. P&A staff may contact Regina Hill inCPR's Newton, Massachusetts office for more information (617-965-0776).
    A bibliography of articles on Ethnic Psychopharmacology follows a chart listing importantresearch findings by ethnic background.
Ethnic Psychopharmacology
Research Findings Chart

(Numbers are references to the articles listed below the chart)

African Americans
 

Asians
 

Hispanics
 

A higher rate of misdiagnosisand over-medication (2,3,6,7,16,18,38)
 

Better results have been foundwith lower doses of clozaril (7,18,33)
 

Tend to respond better tolower doses of Risperidone (1, 7, 28)
 

Have more side effects withthe standard doses of lithium (2,3,7,8,16,18,31,39)
 

For many Taiwanese the
therapeutic level of lithium islower than the standard range (7,33,39,38)
 

In Latin America, lower dosesof medications are often used,than in the United States andthe rate of improvement isfaster (1,7,28)
 

Higher risks of side effectsfrom TricyclicAntidepressants such as Elaviland Vivactil (3,7)
 

It is best to start at half of thestandard dosage of allpsychiatric medication (5,7,18,19,20,21,33)
 

Tricyclic antidepressant sideeffects like dry mouth,impaired vision, and weightgain, are seen at half the dosesgiven to European Americans (1,7,28)
 

Tend to have a better andmore rapid response withtricyclic antidepressants whengiven the proper dosage. (2,3,16)
 

Tend to use alternativetreatment methods, such asherbal remedies, which mayeffect responses topsychotropic medication (19,23,33)

 

 

Are more likely to benonresponders to Fluoxetine(Prozac) (2,3,)

 

Tend to metabolize TricyclicAntidepressants more slowlythan Caucasians (18,19,33)
 

 

African Americans

 

Asians
 

Hispanics
 

Tend to have significantlyfaster responses than otherracial groups from benzodiazepines such asAtivan and Halcion (2,3,18)
 

 

 

Higher rate of tardivedyskinesia (16,34,45)
 

 

 

More likely to receive depotmedication (16)
 

 

 

Zyprexa typically works betteras an anti-psychotic (3,10,12,26)
 

 

 

Sources

1.

Adams, G., & Dworkin, R.: Diagnosis and pharmacology issues in the care of Hispanics inthe public sector. American Journal of Psychiatry, 1984; 141, 970-974

2.

Adebimpe, V.: Overview: White norms in psychiatric diagnosis of black American patientsAmerican Journal of Psychiatry, 1981; 138(3), 279-285.

3.

Baker, F.M. Bell, Carl. C.: Issues in the Psychiatric Treatment of African AmericansPsychiatry Services, March 1999 50(3) 362-368

4.

Binder, R. Levy, R., Drs. Binder and Levy Reply; Letters to the Editor American Journal of Psychiatry, 1982; 139(4) 540

5.

Binder RL, Levy R: Extrapryamidal reactions in Asians. American Journal of Psychiatry138: 1243-1244, 1981.

6.

Brown DR, Feroz A, Gary LE, et al: Major depression in a community of AfricanAmerican. American Journal of Psychiatry 152: 373-378, 1995

7.

Caminah-Bacote, J.: Resources in Transcultural Care and Mental Health 13th Edition 2002

8.

Chen YR, Swann AC, Burt DB: Stability of diagnosis in schizophrenia. American Journalof Psychiatry, 153: 682-686, 1996

9.

Collazo Y, Tam R, Sramek J, et al: Neuroleptic dosing in Hispanic and Asian Inpatientwith schizophrenia. Mt Sinai Journal of Medicine, 63:310-313, 1996

10.

Evans WE, Johnson J.: Pharmacogenomics: The inherited basis for interindividualdifferences in drug response. Ann Rev Genomics Hum Genetics 02: 9-39, 2001.

11.

Flaherty JA, Meagher R: Measuring racial bias in inpatient treatment. American Journal ofPsychiatry 137: 679-682, 1980

12.

Frackiewicz, E. J., Sramek, J. J., Herrera, J. M., Kurtz, N. M., & Cutler, N. R.: Ethnicityand antipsychotic response. Annals of Pharmacotherapy, 1997 31, 1360_1369.

13.

Gaw A: Culture, Ethnicity, and Mental Illness. Washington , DC, American PsychiatricPress, 1993

14.

Guarnaccia PJ, Good BJ, Kleinman A: A critical review of epidemiological studies ofPuerto Rican mental health. American Journal of Psychiatry, 147:1449-1456, 1990

15.

Hu, T. W., Snowden, L. R., Jerrell, J. M., & Nguyen, T. D.: Ethnic populations in publicmental health: Services choice and level of use. American Journal of Public Health 1991,81, 1429_1434.

16.

Lawson, WB: Issues In Pharmacotherapy for African Americans in Ethnicity andPsychopharmacology. Edited by Pedro Ruiz ( Review of Psychiatry Series, Vol. 19, No. 4Oldham JO and Riba MB, series eds.). Washington, DC, American Psychiatric Press,2000. pp 37-47

17.

Lawson WB, Helper N, Holladay J, Et al: Race as a factor in inpatient and outpatientadmissions and diagnosis. Hospital and Community Psychiatry 45:72-74, 1994

18.

Lin KM, Poland RE: Ethnicity, Culture and Psychopharmacology: Psychopharmacology:The Fourth Generation of Progress. 1995; 162:1907-1017

19.

Lin, KM., Cheung, F., Mental Health issues for Asian Americans. Psychiatry Services1999 Jun;50(6) 774-780

20.

Lin, Km. Poland, R. Nuccio, I., Matsuda, K., Hathuc, N., Su, T., & Fu, P. A longitudinalassessment of Haloperidol doses and serum concentrations in Asian and Caucasianschizophrenic patients. American Journal of Psychiatry. 1989; 146, 1307-1311

21.

Lin, KM., Finder, E.: Neuroleptic Dosage for Asians. American Journal of Psychiatry,1983; 140:490-491

22.

Lin, KM., Anathan, J: Physical and Ethnic Variables in Dosage for Asians AmericanJournal of Psychiatry , 1982 139 (4): 539-540

23.

Lin, KM., Smith, MW.: Psychopharmacotherapy in the Context of Culture and Ethnicityin Ethnicity and Psychopharmacology. Edited by Pedro Ruiz ( Review of PsychiatrySeries, Vol. 19, No. 4 Oldham JO and Riba MB, series eds.). Washington, DC, AmericanPsychiatric Press, 2000. pp 1-27

24.

Lin KM: Psychopharmacology in Cross-cultural Psychiatry: Mt. Sinai Journal of MedicineOct/Nov 1996; 63: 283-284.

25.

Lin KM, Mendoza RP, Smith Michael W.:Gender and Ethnic Differences in thePharacogenetics of Psychotropics Research Center of Psychobiology of Ethnicity and theDepartment of Psychiatry, UCLA School of Medicine, Harbor-UCLA Medical Center

26.

Lindamer L, Lacro JP, Jeste DV: Relationship of ethnicity to the effects of antipsychoticmedication, in Cross Cultural Psychiatry, Edited by Herrera JM, Lawson WB, Sramek JJ.New York Wiley, 1999, pp 193-203

27.

Marcel J. de Groot, Ackland M., Horner V., Alex A., Jones B.: A Novel Approach toPredicting P450 Mediated Drug Metabolism. CYP2D6 Catalyzed N-DealkylationReactions and Qualitative Metabolite Predictions Using a Combined Protein andPharmacophore Model for CYP2D6. Journal of Medical Chemistry 1999, 42: 4062-4070

28.

Mendoza R, Smith MW,: The Hispanic Response to Psychotropic Medications inEthnicity and Psychopharmacology. Edited by Pedro Ruiz ( Review of Psychiatry Series,Vol. 19, No. 4 Oldham JO and Riba MB, series eds.). Washington, DC, AmericanPsychiatric Press, 2000. pp 55-82

29.

Mendoza R, Smith MW, Poland, RE, Lin Km, Strickland TL: Ethnic Psychopharmacology: The Hispanic and Native American Perspective.Psychopharmacology Bulletin. 1991;27:449-461.

30.

Moss G.P. The Nomenclature of Multiple Forms of Enzymes; Recommendations (1976)http://www.chem.qmul.ac.uk/iubmb/misc/isoen.html

31.

Okpaku Sincerely, Frazer A, Mendels J: A pilot study of racial differences in erythrocytelithium transport. American Journal of Psychiatry 137:120-121, 1980

32.

Paul Murphy Annie: Painting Insanity Black? Why are more blacks schizophrenics? www.salon.com December 1999.

33.

Pi EH, Gray GE.: Ethnopsychopharmacolgy for Asians in Ethnicity andPsychopharmacology. Edited by Pedro Ruiz ( Review of Psychiatry Series, Vol. 19, No. 4Oldham JO and Riba MB, series eds.). Washington, DC, American Psychiatric Press,2000. pp 91-108

34.

Pi EH, Gutierrez Ma, Gray GE: Tardive Dyskinesia: cross-cultural perspectives, inPsychopharmacology and Psychobiology of Ethnicity. Edited by Lin K-M, Poland RE,Nagasaki G. Washington, DC America Psychiatric Press, 1993 pp 153-167

35.

Price N, Glazer WM, Morgenstern H: Race and the use of fluphenazine deconate.American Journal of Psychiatry, 142:1491-1492, 1985.

36.

Rosenheck R, Fontana A, Cottrol C: Effect of clinician-veteran racial pairing in thetreatment of post traumatic stress disorder. American Journal of Psychiatry, 152:555-563,1995

37.

Ruiz P,: The role of cultural in psychiatric care. American Journal of Psychiatry,155:1763-1765, 1998

38.

Ruiz P, Varner RV, Small DR, et al: Ethnic differences in the neuroleptic treatment ofschizophrenia. Psychiatry Quarterly 70"163-170, 1999.

39.

Stephens EA, Taylor JA, Yang CH, et al: Ethnic variation in the CYP2E1 gene:polymorphism analysis of 495 African- Americans, European-Americans and Taiwanese.Pharacogenetics 4:185-192, 1994.

40.

Strickland TL, Stein R, Lin KM, Risby Emile, Fong R: The Pharmacologic Treatment ofAnxiety and Depression in African Americans. Archives of Family Medicine, 6:371-374July/Aug, 1997.

41.

Strickland TL, Ranganath V, Lin KM et al: Psychopharmacologic considerations in t hetreatment of black American populations. Psychopharmacology Bulletin 27: 441-118, 1991

42.

Varner RV, Ruiz P, Small DR.: Ethnopsychopharmacolgy in the Public Sector in Ethnicityand Psychopharmacology. Edited by Pedro Ruiz ( Review of Psychiatry Series, Vol. 19,No. 4 Oldham JO and Riba MB, series eds.). Washington, DC, American PsychiatricPress, 2000. pp 115-127

43.

Sue S, Fujino DC, Hu LT, et al: Community mental health services for ethnic minoritygroups: a test of the cultural responsiveness hypothesis, J Consult Clin Psychol 59: 533-
540, 1991

44.

Svensson CK: Representation of American blacks in clinical trials of new drugs. JAMA261:263-265, 1989

45.

Swartz R, Burgoyne K, Smith M et al: Tardive dyskinesia and ethnicity: review of theliterature. Annals of Clinical Psychiatry 9:53-59, 1997

46.

Toland AE: Genetic 101 DNA Mutations, www.genetichealth.com lat update January3,2001

47.

Yamamoto J, James QC, Bloombaum M, et al: Racial factor in patient selection. AmericanJournal of Psychiatry, 124: 630-636, 1967

Footnote: 1    For example, there is evidence that metabolic absorption rates and side effects vary inethnic minorities. This could contribute to “treatment resistance” by some individuals, raising thechance for forced treatment.

Footnote: 2     This study was of patients from Puerto Rico and the Dominican Republic.Footnote: 3     Informed consent laws vary from state to state and most jurisdictions have exceptions forpeople with mental disabilities in certain circumstances. A full description of the law of informedconsent and the right to refuse treatment is beyond the scope of this Q&A. However, pertinentmaterials are available on the NAPAS web site. For a very recent discussion about therequirement for informed consent in the context of experimental medical therapies see Heinrich vSweet, ___F.3d ___ 2002 WL 1941483 (1st Cir 2002). A helpful discussion of informed consent,again in the medical context, can be found at Harnish v Children's Hospital Medical Center, 439N.E.2d 240 (Mass. Sup. Jud. Ct. 1982)

To save files, right click and choose 'Save Target As' or 'Save Link As'
File Attachment: 
AttachmentSize
File Q_A_ethnic_psychopharm.wpd36.64 KB

Limit Offer